Precision Medicine

Eli Lilly's strategic buyout of a Texas biotech isn't just a deal; it's a bet on a new scientific paradigm to solve the chronic pain crisis without opioids.

In a strategic pivot, GeneDx brings in former Quest and Thermo Fisher exec Mark Gardner to translate its genomic leadership into commercial dominance.

Arima Genomics' award-winning Aventa test is revolutionizing lymphoma diagnostics by seeing cancer in 3D, moving beyond 2D methods to find what others miss.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

LRM Aesthetics' new delivery system for its PDGF+ formula isn't just a product update; it’s a masterclass in how small innovations create major workflow gains.

Pluristyx secures a key Japanese patent for its rapid mRNA reprogramming tech, slashing iPSC production time and promising to unlock commercial-scale cell therapy.

German firm NVision wins a top award for POLARIS, a quantum-enhanced MRI platform that shows if cancer therapy is working weeks or months sooner.

Verge Labs' new AI model promises to predict brain activity from a blood draw, potentially upending the costly and failure-prone world of neurology R&D.

Renowned cancer researcher Dr. Morag Park takes the helm at the Gairdner Foundation, a key predictor of Nobel Prizes. What does this strategic move mean for global science?

Preliminary data from a randomized trial suggests a personalized medicine approach can reverse cognitive decline, offering a glimmer of hope beyond slowing the disease.

NeoGenomics is raising $275M via convertible notes. We dissect the sophisticated financing, from dilution-hedging calls to the market impact for investors.

A new strategic partnership aims to overcome drug resistance in GI cancers by combining Lonza's advanced ADC platform with Antharis's targeted antibody expertise.

A new wave of advanced cancer drugs is set to upend the market. As the EGFR inhibitor space surges towards $16B, we analyze the strategies behind the disruption.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

With a $50M seed round, Radical Numerics aims to build general biological intelligence, walking a fine line between curing disease and creating bioweapons.

As Orca Bio builds a manufacturing empire from Sacramento to Princeton, it's not just preparing for a new drug launch—it's trying to solve the biggest puzzle in biotech.

A new precision drug, ART5803, is offering hope for a devastating brain disorder. Arialys Therapeutics is fast-tracking its development with key clinical trials.

Fate Therapeutics' new board appointment signals a major shift. Can a commercial veteran turn groundbreaking iPSC science into accessible, off-the-shelf medicine?

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.